Applied Fundamental Research’s PetIQ, Inc. Class A Common Stock PETQ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-219,076
Closed -$6.74M 13
2024
Q3
$6.74M Sell
219,076
-405,000
-65% -$10.9M 4.45% 10
2024
Q2
$13.8M Sell
624,076
-9,454
-1% -$182K 10.13% 6
2024
Q1
$11.6M Sell
633,530
-20,696
-3% -$368K 8.58% 8
2023
Q4
$12.9M Sell
654,226
-132,742
-17% -$2.55M 9.32% 7
2023
Q3
$15.5M Sell
786,968
-806,618
-51% -$14.4M 11.27% 2
2023
Q2
$24.2M Buy
1,593,586
+9,107
+0.6% +$117K 15.16% 2
2023
Q1
$18.1M Sell
1,584,479
-49,383
-3% -$548K 13.06% 2
2022
Q4
$15.1M Hold
1,633,862
10.84% 3
2022
Q3
$11.3M Buy
1,633,862
+534,344
+49% +$7.21M 9.15% 7
2022
Q2
$18.5M Buy
1,099,518
+154,007
+16% +$2.83M 10.3% 6
2022
Q1
$23.1M Buy
945,511
+176,291
+23% +$3.71M 10.39% 3
2021
Q4
$17.5M Buy
769,220
+141,646
+23% +$3.31M 8.4% 7
2021
Q3
$15.7M Buy
+627,574
New +$18.9M 8.39% 7

Other funds holding PETQ

Applied Fundamental Research's PETQ Position: Q4 2024 in Review

Applied Fundamental Research sold out of PetIQ, Inc. Class A Common Stock (PETQ) in Q4 2024, closing a stake of 219,076 shares — an estimated $6.74M sold.

Applied Fundamental Research first reported a position in PETQ in Q3 2021 and held it in 13 quarters. The position peaked at $24.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold PETQ as of Q4 2024.

  • Applied Fundamental Research reported no remaining PetIQ, Inc. Class A Common Stock position as of Q4 2024 after selling out during the quarter.
  • Applied Fundamental Research sold 219,076 PetIQ, Inc. Class A Common Stock shares in Q4 2024, an estimated $6.74M.
  • Applied Fundamental Research first reported a position in PetIQ, Inc. Class A Common Stock in Q3 2021 and held it in 13 quarters.
  • Applied Fundamental Research's PetIQ, Inc. Class A Common Stock position peaked at $24.2M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held PetIQ, Inc. Class A Common Stock as of Q4 2024.

Based on Applied Fundamental Research's 13F filing for Q4 2024, filed 10 Feb 2025.